COMMUNIQUÉS West-GlobeNewswire

Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds
25/06/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2025 Idorsia Ltd (SIX: IDIA) today announced the launch of the repurchase offer to the holders of its outstanding CHF 200 million convertible [...]
LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park
25/06/2025
LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park London, 25 June 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in [...]
OSE Immunotherapeutics met à jour l’information sur les procédures en cours
25/06/2025
OSE Immunotherapeutics met à jour l’information sur les procédures en cours NANTES, France, 25 juin 2025, 8 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) annonce qu’à la suite de l’audience le [...]
OSE Immunotherapeutics provides an update on ongoing proceedings
25/06/2025
OSE Immunotherapeutics provides an update on ongoing proceedings Nantes, June 25 th , 2025, 8:00 a.m. - OSE Immunotherapeutics SA ( ISIN: FR0012127173; Mnemo: OSE), announces that, following the hearing on June 24th, [...]
Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director
25/06/2025
Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director Egham, UK – 25 June 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing [...]
Actimed Therapeutics Enrolls First Patients in Phase 2a PROACT Study Programme to Assess S-pindolol benzoate in Obese Patients During and Post-GLP-1 Agonist Therapy
25/06/2025
Two-part clinical study programme to evaluate change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst 1) receiving the GLP-1 agonist semaglutide; and 2) after cessation of [...]
Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)
25/06/2025
The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease [...]
Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements
25/06/2025
Not for dissemination in the United States of America VANCOUVER, British Columbia, June 24, 2025 (GLOBE NEWSWIRE) -- Aja Health and Wellness Inc. ("Aja" or the "Company") (TSXV:Aja) announces that it is getting closer [...]
Cidara Announces Pricing of Upsized Public Offering of Common Stock
25/06/2025
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today [...]
Une première autorisation de distribution de la fleur de cannabis médicinal à des fins thérapeutiques délivrée par le ministère de la Santé italien pour Tilray Medical
25/06/2025
SAVONE, Italie, 25 juin 2025 (GLOBE NEWSWIRE) -- Tilray Medical, ci-après « Tilray », une division de Tilray Brands, Inc. (NASDAQ : TLRY et TSX : TLRY) et un leader mondial du cannabis thérapeutique permettant aux [...]
Shiny Smile Veneers Named Top Snap-On Veneer Brand in the US by Independent Review Platforms
24/06/2025
Houston, TX, June 24, 2025 (GLOBE NEWSWIRE) -- Shiny Smile Veneers, a US-based provider of custom-made snap-on veneers, has once again been recognized as one of the top snap-on veneer brands in the country, this time by [...]
Abvance Therapeutics Secures Strategic Seed Financing & Leadership Expansion at ADA Scientific Sessions
24/06/2025
CHICAGO, June 24, 2025 (GLOBE NEWSWIRE) -- Abvance Therapeutics, a biotechnology company developing next-generation glucagon analogs and therapies to prevent hypoglycemia and improve glucose management, today announced [...]
Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
24/06/2025
– PDUFA action date set for October 25, 2025 – – sNDA being reviewed under FDA’s RTOR program – – Revumenib has the potential to become the first and only menin inhibitor approved in both R/R mNPM1 AML and R/R KMT2Ar [...]
Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium
24/06/2025
NORWOOD, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will [...]
InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke
24/06/2025
MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (the “Company”) (Nasdaq: NSPR), developer of the CGuard Prime Carotid Stent System for the prevention of stroke, today announced that the U.S. Food and Drug [...]
BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress
24/06/2025
CARSON CITY, Nev., June 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and [...]
NeuroPace Announces Strategic CFO Transition
24/06/2025
Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Role MOUNTAIN VIEW, [...]
Administrative Law Judge Determines ReWalk Personal Exoskeleton is “Reasonable and Necessary” for Medicare Beneficiary
24/06/2025
Decision at the highest levels of appeal in the Medicare process establishes medical necessity of the ReWalk Exoskeleton for enabling paralyzed individuals to stand and walk in everyday environments. MARLBOROUGH, Mass. [...]
Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market
24/06/2025
GAITHERSBURG, Md., June 24, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused [...]

Pages